• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.

    5/15/26 6:12:11 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NSRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Nasus Pharma Ltd

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)




    IL001218553

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    IL001218553


    1Names of Reporting Persons

    Balyasny Asset Management L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,169,910.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,169,910.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,169,910.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP Number(s):
    IL001218553


    1Names of Reporting Persons

    BAM GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,169,910.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,169,910.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,169,910.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    IL001218553


    1Names of Reporting Persons

    Balyasny Asset Management Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,169,910.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,169,910.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,169,910.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP Number(s):
    IL001218553


    1Names of Reporting Persons

    Dames GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,169,910.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,169,910.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,169,910.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    IL001218553


    1Names of Reporting Persons

    Dmitry Balyasny
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,169,910.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,169,910.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,169,910.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nasus Pharma Ltd
    (b)Address of issuer's principal executive offices:

    29 Harakevet Street, Tel Aviv, Israel 6618003
    Item 2. 
    (a)Name of person filing:

    This statement is being filed by (1) Balyasny Asset Management L.P., a Delaware limited partnership ("BAM"), (2) BAM GP LLC, a Delaware limited liability company ("BAM GP"), (3) Balyasny Asset Management Holdings LP, a Delaware limited partnership ("BAM Holdings"), (4) Dames GP LLC, a Delaware limited liability company ("Dames"), and (5) Dmitry Balyasny, a United States citizen (collectively, the "Reporting Persons"). BAM GP is the General Partner of BAM. BAM Holdings is the Sole Member of BAM GP. Dames is the General Partner of BAM Holdings. Dmitry Balyasny is the Managing Member of Dames.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
    (c)Citizenship:

    (1) BAM is a Delaware limited partnership, (2) BAM GP is a Delaware limited liability company, (3) BAM Holdings is a Delaware limited partnership, (4) Dames is a Delaware limited liability company, and (5) Mr. Balyasny is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.01 per share
    (e)CUSIP Number(s):

    IL001218553
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    By virtue of its position as the investment manager of Atlas Private Holdings (Cayman) Ltd. ("APHC"), the direct holder of the 1,169,910 shares of common stock (including 271,437 shares issuance upon exercise of warrants), par value $0.01 per share, reported herein, BAM may be deemed to exercise voting and investment power over such Shares held by APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by APHC and thus may be deemed to beneficially own such Shares. By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by APHC and thus may be deemed to beneficially own such Shares.
    (b)Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares, based on 11,710,808 Shares outstanding as of March 27, 2026, as reported in the Issuer's post-effective amendment to its registration statement on form F-1 filed with the Securities and Exchange Commission on March 27, 2026. The report amount consists of 898,473 shares and 271,437 shares issuable upon the exercise of 898,473 Warrants subject to the Beneficial Ownership Limitation (as defined herein). The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the "Beneficial Ownership Limitation").
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Each of the Reporting Persons has the sole power to vote or to direct the vote of 1,169,910 shares.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Each of the Reporting Persons has the sole power to vote or to direct the vote of 1,169,910 shares.

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    APHC, a Cayman Islands exempted company that is an investment management client of BAM, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Balyasny Asset Management L.P.
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    BAM GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Balyasny Asset Management Holdings LP
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Dames GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Dmitry Balyasny
     
    Signature:/s/ Dmitry Balyasny
    Name/Title:Dmitry Balyasny / Self
    Date:05/11/2026
    Get the next $NSRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSRX
    SEC Filings

    View All

    SEC Form 6-K filed by Nasus Pharma Ltd.

    6-K - Nasus Pharma Ltd (0002029039) (Filer)

    6/9/26 4:06:36 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Nasus Pharma Ltd.

    S-8 - Nasus Pharma Ltd (0002029039) (Filer)

    5/26/26 5:20:14 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.

    SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)

    5/15/26 6:12:11 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    6/22/26 7:12:42 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    6/22/26 7:12:42 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Teleman Dan Benjamin

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    4/22/26 9:44:10 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Teleman Dan Benjamin

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    4/1/26 7:31:31 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

    TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management will present live at the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, to be held virtually on June 24-25, 2026. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Nasus invites individual and institutional investors, as well as advisors and

    6/22/26 8:00:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

    Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic ("PK") and safety study of NS003, the Company's proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting. Ondanse

    6/9/26 8:00:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Financials

    Live finance-specific insights

    View All

    BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

    In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind

    3/19/26 10:05:58 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

    NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),

    3/16/26 7:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

    TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at

    3/9/26 8:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Leadership Updates

    Live Leadership Updates

    View All

    Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

    TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma's executive leadership team. Mr. Rubin will lead and oversee Nasus Pharma's financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as

    11/20/25 8:15:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care